ClinicalTrials.gg
CompletedNCT03202394Updated Jun 25, 2020

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

A Phase 2 interventional study of BIO-11006 and Placebo in Respiratory Distress Syndrome, Adult, sponsored by BioMarck Pharmaceuticals, Ltd.. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-25.

Sponsored by BioMarck Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 7 months ago, and no results have been posted to the registry.
Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients. The subjects will be randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus standard of care. The treatment will continue for up to 28 days. The study will enroll up to 40 adult ARDS patients in up to eight sites within USA.

Read the detailed description

This is a randomized, double blind, placebo controlled, parallel-group Phase IIa pilot study of aerosolized BIO 11006 in patients with sepsis-induced acute respiratory distress syndrome (ARDS). All patients enrolled in the study will be ventilated. To be eligible for enrollment, patients must be adults who have sepsis-induced ARDS within 48 hours prior to enrollment, require intubation, and exhibit bilateral infiltrates consistent with pulmonary edema on the frontal chest radiograph within 48 hours of enrollment. Patients will be randomized in a 1:1 ratio to either BIO-11006 125 mg twice daily (BID) plus standard of care ventilation or placebo (half normal saline [HNS]) BID plus standard of care ventilation. Patients randomized to receive BIO-11006 or placebo will start dosing at the time of ventilation and continue for up to 28 days or length of ventilation (if shorter). Patients in both groups will receive best available standard of care treatment, including low-volume mechanical ventilation as indicated by clinical judgment and patient response. The maximum duration of treatment will be 30 days.

The primary objective of this study is to evaluate the safety and efficacy of aerosolized BIO-11006 at a dose of 125 mg BID in ventilated patients who have ARDS. Safety is the primary endpoint in this study and will be monitored by adverse event reporting, oxygenation, mortality, vital signs, ventilator-free days, and ICU-free days.

This study will enroll up to 40 adult patients with ARDS induced by sepsis who first met the Berlin Criteria for ARDS within 48 hours of enrollment, and who require intubation and exhibit bilateral opacities consistent with pulmonary edema on frontal chest radiograph within 48 hours of enrollment.

BIO 11006 Inhalation Solution drug product is formulated at a dosage strength of 41.67 mg/mL (125 mg/3 mL) as an aqueous solution containing sodium chloride and is intended for aerosol administration by the "Aeroneb Pro®" nebulizer to patients randomized to active treatment.

02

Conditions studied

  • Respiratory Distress Syndrome, Adult

Keywords

  • intubation
  • aerosol
  • sepsis
  • edema
03

In context

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 283 are open to participants now.

This study's enrollment of 38 is below the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

BioMarck Pharmaceuticals, Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided (or relative has) written and authorization for use and disclosure of protected health information
  2. Has a clinical diagnosis of sepsis or septic shock defined as:

    • Known or suspected infection
    • Systemic inflammatory response syndrome (SIRS), defined as meeting at least 2 of the following 3 criteria for a systemic inflammatory response:

      • White blood cell count >12,000 or \<4,000 or >10% band forms
      • Body temperature >38°C (any route) or \<36°C (by core temperatures only: indwelling catheter, esophageal, rectal)
      • Heart rate >90 beats/min or receiving medications that slow heart rate or pace rhythm
  3. Enrollment must occur within 48 hours of first meeting ARDS criteria per the Berlin definition of ARDS (ARDS Task Force 2012) and no more than 72 hours from the initiation of mechanical ventilation. (The bilateral opacities, respiratory failure, and decreased P/F ratio must all be present within a 24 hour time period of one another.):

    • Lung injury of acute onset, within 1 week of an apparent clinical insult, with progression of respiratory symptoms
    • Bilateral opacities on chest imaging not fully explained by effusions, lobar/lung collapse, or nodules.
    • Respiratory failure not fully explained by cardiac failure or fluid overload. (Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk factor present.)
    • Decreased arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FIO2) ratio while on a minimum Positive End Expiratory Pressure (PEEP) of 5 cm water (H2O):

      • Moderate ARDS: 101 to 200 mmHg (≤ 26.6 kPa)
      • Severe ARDS: ≤ 100 mmHg (≤ 13.3 kPa)

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years or >75 years old
  2. Greater than 48 hours since first meeting ARDS criteria per the Berlin definition of ARDS
  3. Pregnant or breastfeeding (negative pregnancy test required prior to randomization for female patients of .)
  4. Prisoner
  5. Any other irreversible disease or condition for which 6 month mortality is estimated to be > 50%
  6. Moderate to severe liver failure ( Score > 12)
  7. Severe chronic respiratory disease with a PaCO2 > 50 mmHg or the use of home oxygen
  8. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
  9. Major trauma in the prior 5 days
  10. Lung transplant patient
  11. No consent/inability to obtain consent
  12. Moribund patient not expected to survive 24 hours
  13. World Health Organization (WHO) Functional Class III or IV pulmonary hypertension
  14. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol
  15. Currently receiving extracorporeal life support or high frequency oscillatory ventilation
  16. Known to BIO 11006
  17. Burn victims >20% Total Body Surface Area (TBSA) or with known airway inhalation injury
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    Active intervention

    Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.

    Drug: BIO-11006

  • Placebo comparator
    Placebo intervention

    Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.

    Drug: Placebo

Interventions

  • Intervention involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer".

  • DrugPlacebo

    Intervention involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer".

    Also known as: Half Normal saline

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Assessment of frequency, type, severity, and duration of treatment-emergent Adverse Events (AE) daily during 28 day treatment period, including clinically significant laboratory abnormalities

    Time frame: 28 days

Secondary outcomes

  1. Incidence of mortality

    Mortality will be assessed daily during treatment for 28 days and at day 180 after enrollment.

    Time frame: End of treatment period (28 days) and end of follow up period (180 days)

  2. Number of Intensive Care Unit (ICU)-free days

    Number of days not in the ICU assessed daily during the 28 day treatment period.

    Time frame: 28 days

  3. Number of ventilator-free days

    Number of days off the ventilator assessed daily during 28 day treatment

    Time frame: 28 days

  4. Change in oxygen saturation / fraction of inspired oxygen (S/F) ratio

    Change in theS/F ratio assessed daily during the 28 day treatment period

    Time frame: 28 days

  5. Change in pro-inflammatory biomarkers from baseline to end of treatment

    ARDS associated biomarkers will be measured in plasma

    Time frame: pretreatment and end of treatment period (28 days)

07

Study locations

5 sites
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • University of North Carolina School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University, Div of Allergy, Pulmonary, Critical Care
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03202394
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Aug 5, 2017
Primary completion
Mar 30, 2020
Completion
Jun 15, 2020
Last update
Jun 25, 2020

Study contacts

Brian Dickson, MD
study chair · Biomarck Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BIO-11006

Start the discussion